Solid Biosciences

Solid Biosciences develops gene therapies and other treatments for Duchenne muscular dystrophy and other neuromuscular and cardiac diseases.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2018
Stage of Initial Investment
Series A
Initial Investment Year
2017